Home » Stocks » Argenx SE

Argenx SE (ARGX)

Stock Price: $252.24 USD -4.56 (-1.78%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $260.00 +7.76 (3.08%) Oct 22, 4:01 PM

Stock Price Chart

Key Info

Market Cap 11.86B
Revenue (ttm) 78.41M
Net Income (ttm) -162.97M
Shares Out 47.01M
EPS (ttm) -1.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $252.24
Previous Close $256.80
Change ($) -4.56
Change (%) -1.78%
Day's Open 246.16
Day's Range 245.72 - 255.53
Day's Volume 212,638
52-Week Range 103.75 - 284.00

More Stats

Market Cap 11.86B
Enterprise Value 10.36B
Earnings Date (est) Mar 4, 2021
Ex-Dividend Date n/a
Shares Outstanding 47.01M
Float 46.93M
EPS (basic) n/a
EPS (diluted) -1.73
FCF / Share 4.00
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 1.30%
Payout Ratio n/a
Shares Short 1.07M
Short Ratio 5.05
Short % of Float 2.29%
Beta 0.86
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 76.77
PS Ratio 151.23
PB Ratio 6.57
Revenue 78.41M
Operating Income -201.85M
Net Income -162.97M
Free Cash Flow 154.45M
Net Cash 1.49B
Net Cash / Share 31.78
Gross Margin 100.00%
Operating Margin -257.44%
Profit Margin -233.50%
FCF Margin 196.98%
ROA -13.50%
ROE -28.35%
ROIC -27.20%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (20)

Buy 13
Overweight 2
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$267.70*
(6.13% upside)
Low
209
Current: $252.24
High
300
Target: 267.70
*Average 12-month USD price target from 20 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Year20192018201720162015
Revenue69.7821.4836.4214.716.85
Revenue Growth224.84%-41.01%147.5%114.66%-
Gross Profit69.7821.4836.4214.716.85
Operating Income-180-81.85-22.93-21.42-15.61
Net Income-163-66.64-28.08-21.37-15.31
Shares Outstanding38.6233.4224.6118.8215.73
Earnings Per Share-4.22-1.99-1.14-1.14-0.97
Operating Cash Flow139-53.27-36.5510.60-13.90
Capital Expenditures-1.60-0.62-0.35-0.84-0.27
Free Cash Flow137-53.90-36.899.76-14.17
Cash & Equivalents1,33656636197.5142.33
Total Debt6.51----
Net Cash / Debt1,32956636197.5142.33
Assets1,43357837110645.96
Liabilities38340.0625.9842.408.68
Book Value1,05153834563.3737.28
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name Argenx SE
Country Netherlands
Employees 186
CEO Tim van Hauwermeiren

Stock Information

Ticker Symbol ARGX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARGX
IPO Date May 18, 2017

Description

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.